UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000030742
Receipt number R000035103
Scientific Title Efficacy and safety of ripasudil hydrochloride in glaucoma patients being treated by prostaglandin analogues, but their intraocular pressures are 15mmHg or under.
Date of disclosure of the study information 2018/01/18
Last modified on 2023/07/20 18:58:26

No. Disposal Last modified on Item of update
1 Insert 2018/01/10 10:05:25
2 Update 2018/01/10 11:16:58 Date of protocol fixation
3 Update 2018/01/18 09:06:43 Public title
Public title
Acronym
Acronym
4 Update 2018/01/18 09:08:11 Narrative objectives1
Basic objectives2
Primary outcomes
5 Update 2018/01/18 09:20:14 Basic design
Control
No. of arms
Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
Key inclusion criteria
Key inclusion criteria
6 Update 2018/01/18 09:21:10 Organization
7 Update 2018/01/18 09:22:13 Recruitment status
8 Update 2020/07/13 19:03:47 Recruitment status
Date of IRB
Anticipated trial start date
Last follow-up date
9 Update 2020/10/13 07:12:40 Study type
Basic design
Randomization
Blinding
Control
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_1
Key inclusion criteria
Key inclusion criteria
10 Update 2020/11/04 09:59:09 Last follow-up date
Other related information
Other related information
11 Update 2023/07/19 19:31:09 Recruitment status
12 Update 2023/07/20 17:49:51 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
13 Update 2023/07/20 18:51:06 URL releasing protocol
Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
Plan to share IPD
Plan to share IPD
IPD sharing Plan description
IPD sharing Plan description
14 Update 2023/07/20 18:58:26 Organization1
Address1
Tel1
Email1
Organization
Organization
Address
Address
Tel
Email